LivaNova PLC

NASDAQ:LIVN

Medical - Devices

Healthcare
$94.54 +0.96%

+$0.76 today

Market cap
$5.21B
Beta
0.88
P/E (TTM)
40.5
EPS (TTM)
$1.96
52W Low $41.02High $80.96

Volume 1.32M

Average 0.79M

LIVN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

LivaNova PLCNASDAQ: LIVN

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $47.7M fell 1.9% year over year, behind the +14.5% change in trailing-twelve-month research & development. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Research & development amounted to 13.4% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -1.9% toward the trailing-twelve-month pace of +14.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$47.7M-11.2% QoQ
Last fiscal yearDec 2025
$185.8M+1.8% YoY
LTMSep 2026
$202.57M+14.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.9%——
1 year+1.8%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
185.8M USD
Year-over-year change
+1.8%
4-year CAGR
+0.3%

Research & Development vs competitors

How LIVN compares with its peers on the latest reported figures

  • LIVN's LTM Sep 2026 research & development of $202.57M is the 5th highest of the 10 companies compared; the peer median is $99.68M.
  • Its year-over-year change of +14.5% is the 2nd highest of 10, against a peer median of +4.9%.
  • Research & development amounts to 13.4% of revenue for LIVN, versus a peer median of 10.3%.
LIVN Competitors Peer median
Research & Development for LIVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$2.92B +4.9%+2.1%7.8%
BSXBoston Scientific CorporationLTM Jun 2026$2.15B +17.3%+15.8%10.3%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.09B +3.3%+4.5%16.7%
RMDResMed Inc.LTM Jun 2026$378.28M +14.2%+9.6%6.7%
LIVNLivaNova PLCLTM Sep 2026$202.57M +14.5%+6.0%13.4%
INSPInspire Medical Systems, Inc.LTM Jun 2026$99.68M -9.7%+14.5%11.1%
HAEHaemonetics CorporationLTM Jun 2026$59.46M -4.4%+0.6%4.4%
NPCENeuroPace, Inc.LTM Mar 2026$27.64M +9.2%+8.3%27.8%
CVRXCVRx, Inc.LTM Mar 2026$11.7M +10.5%+3.8%19.8%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M -47.4%-11.0%4.2%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding LIVN) $99.68M+4.9%+4.5%10.3%

Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.04B1.02B1.15B1.25B1.39B
Cost of Revenue329.37M314.58M382.3M382.56M448.2M
Gross Profit705.99M707.23M771.25M870.87M939.9M
Gross Margin68.2%69.2%66.9%69.5%67.7%
Research & Development183.41M155.81M193.82M182.51M185.8M
Selling, General & Admin471.9M469.24M518.13M526.27M548.8M
Operating Expenses706.78M783.98M839.75M741.82M740.5M
Depreciation & Amortization67.99M57.8M60.86M51.14M42M
EBITDA(6.33M)30.9M38.48M202.52M(129.5M)
EBITDA Margin-0.6%3.0%3.3%16.2%-9.3%
Operating Income(784K)(76.75M)(68.5M)129.05M199.4M
Operating Margin-0.1%-7.5%-5.9%10.3%14.4%
Interest Income435K4.7M22.01M30.08M18.98M
Interest Expense50.15M48.25M58.85M63.07M49.29M
Other Income / Expenses(123.84M)1.56M(12.83M)(40.74M)(420.2M)
Income Before Tax(124.62M)(75.2M)(81.33M)88.31M(220.8M)
Pre-Tax Margin-12.0%-7.4%-7.1%7.0%-15.9%
Income Tax Expense11.2M11.05M(98.88M)25.06M21.6M
Net Income(135.82M)(86.25M)17.55M63.23M(242.5M)
Net Margin-13.1%-8.4%1.5%5.0%-17.5%
EPS (Basic)(2.68)(1.61)0.331.17(4.45)
EPS (Diluted)(2.68)(1.61)0.321.16(4.45)
Weighted Avg Shares50.63M53.5M53.9M54.24M54.5M
Weighted Avg Shares (Diluted)50.63M53.5M54.21M54.57M54.5M

LivaNova PLC

NASDAQ:LIVN

Intrinsic Alpha fair value

Locked

Current Price

$94.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.